BAI Stock Overview
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BenevolentAI S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.68 |
| 52 Week High | €2.66 |
| 52 Week Low | €0.48 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -13.92% |
| 1 Year Change | -66.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.13% |
Recent News & Updates
Recent updates
We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate
Dec 23
BenevolentAI S.A. (AMS:BAI) Analysts Just Trimmed Their Revenue Forecasts By 24%
Jun 22BenevolentAI S.A. (AMS:BAI) Analysts Just Cut Their EPS Forecasts Substantially
Apr 26BenevolentAI S.A. (AMS:BAI) Analysts Just Slashed This Year's Revenue Estimates By 20%
Apr 08Will BenevolentAI société anonyme (AMS:BAI) Spend Its Cash Wisely?
Dec 10We're Keeping An Eye On BenevolentAI société anonyme's (AMS:BAI) Cash Burn Rate
Jul 23Shareholder Returns
| BAI | NL Pharmaceuticals | NL Market | |
|---|---|---|---|
| 7D | 3.0% | 3.4% | -0.1% |
| 1Y | -66.0% | 8.2% | 16.2% |
Return vs Industry: BAI underperformed the Dutch Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: BAI underperformed the Dutch Market which returned 18% over the past year.
Price Volatility
| BAI volatility | |
|---|---|
| BAI Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in NL Market | 7.9% |
| 10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: BAI's share price has been volatile over the past 3 months.
Volatility Over Time: BAI's weekly volatility has decreased from 20% to 9% over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 248 | Joerg Moeller | www.benevolent.com |
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson’s disease.
BenevolentAI S.A. Fundamentals Summary
| BAI fundamental statistics | |
|---|---|
| Market cap | €82.92m |
| Earnings (TTM) | -€73.86m |
| Revenue (TTM) | €8.55m |
9.7x
P/S Ratio-1.1x
P/E RatioIs BAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAI income statement (TTM) | |
|---|---|
| Revenue | UK£7.33m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£7.33m |
| Other Expenses | UK£70.65m |
| Earnings | -UK£63.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -863.69% |
| Debt/Equity Ratio | 0% |
How did BAI perform over the long term?
See historical performance and comparison